CellFE Inc., an Alameda, CA-based life sciences tools company developing a microfluidics-based cell engineering platform dedicated to advancing development and manufacturing of advanced cell therapies, closed a $22m Series A financing.
The round was led by M Ventures, with participation from Great Point Ventures and Riverine Ventures as well as existing investors Cota Capital, Dynamk Capital, Elm Street Ventures, Embark Ventures, EGB Capital, and Khosla Ventures.
The company intends to use the funds to advance the development of its technology platform and support market launch and continued growth initiatives.
Led by Alla Zamarayeva, CEO, CellFE leverages a microfluidic-based cell engineering platform with high cell health and payload delivery, streamlined scalability and automated workflows. Platform benefits include increased cell yield and reduced expansion times that translate to reduced vein-to-vein times and manufacturing costs currently associated with advanced cell therapies.
FinSMEs
27/09/2023